Source - LSE Regulatory
RNS Number : 6878S
Oncimmune Holdings PLC
07 November 2023



Oncimmune Holdings plc


("Oncimmune" or the "Company")


Grant of Options and PDMR Dealing



Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, today announces that as part of its management incentivisation scheme, options ("Options") to subscribe for 589,971 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted on 7 November 2023 to Martin Gouldstone, Chief Executive Officer.


Following this grant, Mr Gouldstone holds Options over a total of 589,971 Ordinary Shares, representing approximately 0.8 per cent of the Company's issued share capital of 74,142,147.  Other than the grant of the Options, neither Mr Gouldstone nor any of his connected persons have any beneficial interest in Ordinary Shares.


The Options have been granted under the Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plan, have an exercise price of £0.1695, being the closing price of Ordinary Shares on 6 November 2023 and vest annually in five equal parts from the date of grant until the fifth anniversary of the grant.


This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.


Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.




Details of the person discharging managerial responsibilities / person closely associated







Mr Martin Gouldstone



Reason for the notification







Chief Executive Officer



Initial notification /Amendment



Initial Notification



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor







Oncimmune Holdings plc









Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted





Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

Identification code




Nature of the transaction



Grant of options



Price(s) and volume(s)







Aggregated information

N/A - single transaction

- Aggregated volume

- Price



Date of the transaction

7 November 2023


Place of the transaction

Outside a trading venue




For further information:


Singer Capital Markets (Nominated Adviser and Broker)

Phil Davies, Harry Gooden, James Fischer

+44 (0)20 7496 3000


Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000


About Oncimmune


Oncimmune is a global leader in immune biomarkers and immunodiagnostics, offering autoantibody biomarker profiling in immunooncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the Company provides insights and analytics to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Oncimmune Holdings PLC (ONC)

+0.60p (+2.79%)
delayed 17:30PM